Molecular-Guided Therapy for Childhood Cancer
Learn more about:
Related Clinical Trial
Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
CD30 CAR for CD30+ NSGCT
Molecular Epidemiology of Pediatric Germ Cell Tumors
Multidisciplinary Approach to Fatigue
A Study of DS-9606a in Patients With Advanced Solid Tumors
Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Hepatocellular Carcinoma
A Phase II Trial Evaluating the Efficacy of Cabozantinib With Patients With Refractory GCTs
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
A Study of a New Way to Treat Children With a Brain Tumor Called NGGCT
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Symptom Management for YA Cancer Survivors
A Study of miRNA 371 in Patients With Germ Cell Tumors
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
Molecular-Guided Therapy for Childhood Cancer
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Aflac ST0901 CHOANOME – Sirolimus in Solid Tumors
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
A Pilot RCT of the PRISM Intervention for AYAs With Cancer
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven’t Responded to Therapy
ABT-751 in Treating Young Patients With Refractory Solid Tumors
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Collecting and Storing Tissue From Young Patients With Cancer
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors
Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS)
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
Everolimus in Refractory Testicular Germ Cell Cancer
First Line TIP in Poor Prognosis TGCTs.
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma
Disulfiram and Cisplatin in Refractory TGCTs.
Role of Axumin PET Scan in Germ Cell Tumor
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors
Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors
Study Evaluating the Impact of Short Message Service on Compliance With Surveillance of Patients With Germ-cell Tumors
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Treatment Outcome and Quality of Life in Patients With Pediatric Extra-Cranial Germ Cell Tumors Previously Treated on Clinical Trial CCLG-GC-1979-01 or CCLG-GC-1989-01
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors
Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors
Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors
Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors
Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis
A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis
Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors
Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors
Accelerated v’s Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors
Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors
Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors
Germ Cell Tumor and Testicular Tumor DNA Registry
A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors